

Chemotherapy Protocol

GASTROINTESTINAL (UPPER) CANCER

CAPECITABINE-CISPLATIN-TRASTUZUMAB

Regimen

• Gastrointestinal (Upper) Cancer – Capecitabine-Cisplatin-Trastuzumab

Indication

- Trastuzumab, in combination with capecitabine and cisplatin is recommended as an option for the treatment of people with human epidermal growth factor receptor 2 (HER2) positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior treatment for their metastatic disease and who have tumours expressing high levels of HER2
- WHO performance status 0, 1, 2

Toxicity

Drug	Adverse Effect
Capecitabine	Palmar-plantar erythrodysesthesia, diarrhoea, mucositis, chest pain
Cisplatin	Neuropathy, nephrotoxicity, ototoxicity
Trastuzumab	Cardio toxicity, acute respiratory distress syndrome, infusion related effects

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Monitoring

Regimen

- Prior to starting therapy confirm a positive HER2 status
- FBC, LFT's and U&E's prior to day one of treatment
- Cardiac function must be assessed prior to starting trastuzumab and twelve weekly thereafter unless there are signs of cardiac impairment where four to eight weekly may be more appropriate.
- Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with capecitabine. All patients should be tested for DPD deficiency before initiation (cycle 1) to minimise the risk of these reactions.



Dose Modifications

The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well.

In principle all dose reductions due to adverse drug reactions should not be reescalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped.

Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only.

Haematological

Prior to prescribing the following criteria must be met.

Criteria	Eligible Level		
Neutrophil	equal to or more than 1.5x10 ⁹ /L		
Platelets	equal to or more than 100x10 ⁹ /L		

Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL

If the neutrophils are less than 1.5×10^{9} /L and/or the platelets are less than 100×10^{9} /L then delay treatment for 7 days and re-start treatment at the original dose. If a 14 day delay is required to allow counts to recover or there are two separate delays of 7 days during treatment the dose of the cisplatin should be reduced to 80% of the original dose.

There is little need to adjust the dose of trastuzumab for haematological toxicity.

Hepatic / Renal Impairment

Deteriorating liver or kidney function may be a sign of disease progression or drug toxicity.

Hepatic Impairment

Drug	Dose (% of original dose)
Capecitabine	There is little published information available. No dose reductions are necessary for those with mild to moderate hepatic dysfunction due to liver metastasis
Cisplatin	No dose reduction necessary
Trastuzumab	No dose reduction necessary



Renal Impairment

Drug	Creatinine Clearance (ml/min)	Dose (% of original dose)		
Capecitabine	More than 51	100		
	30-50	75		
	less than 30	Do not use		
Cisplatin	more than 60	100		
	45-59	75		
	less than 45	Consider alternative		
Trastuzumab	No dose adjustment nece	No dose adjustment necessary		

Other

Dose reductions or interruptions in therapy are not necessary for those toxicities that are considered unlikely to be serious or life threatening. For example, alopecia, altered taste or nail changes. Dose limiting toxicities include diarrhoea, abdominal pain, emesis, stomatitis, palmar-plantar erythrodysesthesia and neurosensory toxicities among others.

In general if any NCI-CTC grade 1 toxicity occurs treatment should be continued, without interruption, at the full dose. For toxicities NCI-CTC grade 3 or above, in general, treatment should be withheld until recovery to at least NCI-CTC grade 1 then re-started if medically appropriate. If recovery takes twenty-one days or longer then stop treatment.

Capecitabine

NCI-CTC Grade 2

Interrupt treatment until the toxicity resolves to NCI-CTC grade 0-1 then continue at the same dose. If the toxicity recurs for a second time again interrupt treatment until it resolves to NCI-CTC grade 0-1 then resume therapy at 75% of the original dose. If the same adverse effect develops on a third occasion once more interrupt treatment until it resolves to NCI-CTC grade 0-1 then continue at 50% of the original dose. Stop treatment if the toxicity re-appears on a fourth instance. NCI-CTC Grade 3

Interrupt treatment until the toxicity resolves to NCI-CTC grade 0-1 then continue treatment using 75% of the original dose with prophylaxis if appropriate. If the toxicity recurs for a second time again interrupt treatment until it resolves to NCI-CTC grade 0-1 and then resume therapy at 50% of the original dose. If the same adverse effect develops on a third occasion discontinue capecitabine.

NCI-CTC Grade 4

Discontinue treatment unless the responsible consultant considers it to be in the best interest of the patient to continue at 50% of the original dose once the toxicity has resolved to NCI-CTC grade 0-1.



When capecitabine is stopped for toxicity the doses are omitted, not delayed.

Consider stopping capecitabine therapy if chest pain occurs.

Cisplatin

Neurotoxicity occurring at a NCI-CTC grade 2 or above or a new functional deterioration in hearing and / or tinnitus that does not resolve between cycles should be approached by substituting the cisplatin for carboplatin.

Trastuzumab


Cardiac

The LVEF should be fifty or above before starting cycle one of trastuzumab.

Subsequent Echocardiograms

The flow chart below describes the process to be followed if there is an **asymptomatic** decline in LVEF during trastuzumab treatment.





In general patients who develop **symptomatic** cardiac dysfunction should have trastuzumab discontinued, be commenced on ACE inhibitor therapy and be referred to a cardiologist. Further treatment should be discussed with the relevant oncology consultant.



<u>Regimen</u>

21 day cycle for 6 cycles

The capecitabine and cisplatin are given every 21 days for a maximum of 6 cycles. The trastuzumab is given until disease progression. Six cycles will be set in Aria after which the single agent trastuzumab regimen should be used.

Cycle One

Drug	Dose	Days	Route
Capecitabine	1000mg/m ² twice a day	1-14 incl	Oral
Cisplatin	80mg/m ²	1	Intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin per minute (minimum 120 minutes)
Trastuzumab	8mg/kg	1	Intravenous Infusion in 250ml sodium chloride 0.9% over 90 minutes

Cycle Two Onwards

Drug	Dose	Days	Route
Capecitabine	1000mg/m ² twice a	1-14 incl	Oral
	day		
Cisplatin	80mg/m ²	1	Intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin per minute
Trastuzumab	6mg/kg	1	(minimum 120minutes) Intravenous Infusion in 250ml sodium chloride 0.9% over 30 minutes (if well tolerated at 90 minutes)

Dose Information

- Capecitabine will be dose banded in accordance with the national dose bands
- Cisplatin will be dose banded in accordance with the national dose bands (1mg/ml)
- Trastuzumab will be dose banded in accordance with the national dose bands (21mg/ml)
- If the patient misses a dose of trastuzumab by fourteen days or less, then the usual maintenance dose of 6mg/kg should be given as soon as possible. Do



not wait until the next planned cycle. Subsequent maintenance doses should be given according to the previous schedule

• If the patient misses a dose of trastuzumab by more than fourteen days, a reloading dose of 8mg/kg should be given over 90 minutes. Subsequent maintenance doses should then be given every 21 days from that point

Administration Information

Extravasation

- Cisplatin exfoliant
- Trastuzumab neutral

Other

- Capecitabine should start on the evening of day 1
- Capecitabine should be taken with or after food
- Trastuzumab is associated with hypersensitivity reactions. Patients should be observed for six hours following the start of the first infusion of trastuzumab and for two hours following the start of subsequent infusions. If the patient has tolerated the first two infusions with no infusion related effects consideration can be given to reducing this observation period further

Additional Therapy

Antiemetics

15-30 minutes prior to chemotherapy

- aprepitant 125mg oral
- dexamethasone 4mg oral or intravenous
- ondansetron 8mg oral or intravenous

As take home medication;

- aprepitant 80mg once a day oral for 2 days
- dexamethasone 4mg once a day oral for 3 days
- metoclopramide 10mg three times a day when required oral
- ondansetron 8mg twice a day for 3 days oral
- Cisplatin pre and post hydration as follows;

Pre

Furosemide 40mg oral or intravenous

1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes



Post

1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes

Patients should be advised to drink at least 3 litres of fluid in the 24 hours after administration of cisplatin.

- For treatment of trastuzumab infusion reactions 'once only when required' doses of the following should be prescribed;
 - chlorphenamine 10mg intravenous
 - hydrocortisone 100mg intravenous
 - paracetamol 1000mg oral
- Oral loperamide 4mg after the first loose stool then 2-4mg four times a day when required for the relief of diarrhoea (maximum 16mg/24 hours).
- Mouthwashes according to local or national guidelines for the prevention and treatment of mucositis
- Gastric protection with a proton pump inhibitor or a H₂ antagonist may be considered in patients considered at high risk of GI ulceration or bleed

Additional Information

- The National Patient Safety Agency alert NPSA/2008/RRR001 must be followed when prescribing, dispensing or administering oral chemotherapy.
- Ensure the total daily dose of capecitabine is divided into two doses given twelve hours apart (the first should be administered in the evening of day one of the cycle) Serious toxicity has occurred where the total daily dose has been given twice a day.
- It must be made clear to all staff, including those in the community, that this is a short course of oral chemotherapy that must not be continued.
- Patients should be assessed for suitability for oral chemotherapy prior to starting treatment.

References

Bang YJ, Van Custem E, Fevereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open label, randomised, controlled clinical trial. Lancet 2010; 376 (9742): 687-697.
National Institute for Health and Clinical Excellence (2010). NICE Technology Appraisal Guidance 208. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. DOH: London.



REGIMEN SUMMARY

Capecitabine-Cisplatin-Trastuzumab

Day One Cycle One

1. Trastuzumab 8mg/kg intravenous infusion in 250ml sodium chloride 0.9% over 90 minutes

- 2. Aprepitant 125mg oral
- 3. Dexamethasone 4mg oral or intravenous
- 4. Ondansetron 8mg oral or intravenous
- 5. Furosemide 40mg oral or intravenous

6. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes

7. Cisplatin 80mg/m² intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin/minute (minimum time 120 minutes)

8. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes

9. Chlorphenamine 10mg intravenous when required for infusion related reactions

10. Hydrocortisone 100mg intravenous when required for infusion related reactions

11. Paracetamol 1000mg oral when required for infusion related reactions

Take Home Medicines

12. Capecitabine 1000mg/m² twice a day for 14 days starting on the evening of day one of the cycle oral

13. Aprepitant 80mg once a day for 2 days starting on day two of the cycle oral

14. Dexamethasone 4mg once a day for 3 days starting on day two of the cycle oral

15. Metoclopramide 10mg three times a day when required oral

16. Ondansetron 8mg twice a day for 3 days starting on the evening of day one of the cycle oral

Day One Cycle Two Onwards

1. Trastuzumab 6mg/kg intravenous infusion in 250ml sodium chloride 0.9% over 30 minutes (if well tolerated at 90 minutes)

2. Aprepitant 125mg oral

Version 1.3 (July 2024)



- 3. Dexamethasone 4mg oral or intravenous
- 4. Ondansetron 8mg oral or intravenous
- 5. Furosemide 40mg oral or intravenous

6. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes

7. Cisplatin 80mg/m² intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin/minute (minimum time 120 minutes)

8. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes

9. Chlorphenamine 10mg intravenous when required for infusion related reactions

10. Hydrocortisone 100mg intravenous when required for infusion related reactions

11. Paracetamol 1000mg oral when required for infusion related reactions

Take Home Medicines

12. Capecitabine 1000mg/m² twice a day for 14 days starting on the evening of day one of the cycle oral

13. Aprepitant 80mg once a day for 2 days starting on day two of the cycle oral

13. Dexamethasone 4mg once a day for 3 days starting on day two of the cycle oral

14. Metoclopramide 10mg three times a day when required oral

15. Ondansetron 8mg twice a day for 3 days starting on the evening of day one of the cycle oral



DOCUMENT CONTROL

Version	Date	Amendment	Written By	Approved By
1.3	July 2024	Trastuzumab updated with national dose banding	Alexandra Pritchard Pharmacist	Nanda Basker Pharmacist
1.2	Nov 2020	Updated monitoring with DPD testing Dose banding statement updated Coding removed	Donna Kimber Pharmacy Technician	Rebecca Wills Pharmacist
1.1	May 2014	Header changed Toxicities removed Renal recommendations updated for cisplatin Bolus removed from supportive treatments Metoclopramide dose changed to 10mg Pyridoxine removed from supportive treatments Mouthwashes updated TTOs clarified Disclaimer added	Dr Debbie Wright Pharmacist	Donna Kimber Pharmacy Technician
1	Feb 2012	None	Dr Debbie Wright Pharmacist	Dr Tim Iveson Consultant Medical Oncologist

This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts;

Hampshire Hospitals NHS Foundation Trust NHS Isle of Wight Portsmouth Hospitals NHS Trust Salisbury NHS Foundation Trust University Hospital Southampton NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust

All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors which occur as a result of following these guidelines.